Multiple sclerosis market to generate sales of $29.8 billion by 2030, forecasts GlobalData
Several late-stage pipeline products have the potential to address some of these unmet needs
Several late-stage pipeline products have the potential to address some of these unmet needs
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Transformation to pure-play Innovative Medicines company nears completion
Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study
Subscribe To Our Newsletter & Stay Updated